Compounds > butyroxan
Page last updated: 2024-09-26

butyroxan

Description

butyroxan: analog of propoxan; RN given refers to HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162895
CHEMBL ID1384738
MeSH IDM0075972

Synonyms (26)

Synonym
butyroxan
1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4-(3-phenyl-pyrrolidin-1-yl)-butan-1-one
MLS000031592
smr000011653
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3-phenylpyrrolidin-1-yl)butan-1-one hydrochloride(1:1)
66257-32-7
butyroxane
p4v0eb19ob ,
unii-p4v0eb19ob
omega-(3'-phenyl-1'-pyrrolidinyl)-6-butyrylbenzo(1,4)dioxane
59939-57-0
REGID_FOR_CID_162895
CHEMBL1384738
SR-01000472323-1
sr-01000472323
AKOS030510959
Q4100214
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3-phenylpyrrolidin-1-yl)butan-1-one;hydrochloride
6-(.omega.-(3-phenyl-1-pyrrolidinyl)butyryl)-1,4-benzodioxane-hydrochloride
1-butanone, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3-phenyl-1-pyrrolidinyl)-, hydrochloride (1:1)
1-butanone, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3-phenyl-1-pyrrolidinyl)-, hydrochloride
butyroxan [who-dd]
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3-phenyl-1-pyrrolidinyl)-1-butanone hydrochloride
1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(3-phenylpyrrolidin-1-yl)butan-1-one hydrochloride
DTXSID80975363
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3-phenylpyrrolidin-1-yl)butan-1-one--hydrogen chloride (1/1)

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.00000.044717.8581100.0000AID485294
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686979
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency0.15850.036619.637650.1187AID1466; AID2242
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.15853.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.15853.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (46.15)18.7374
1990's2 (15.38)18.2507
2000's1 (7.69)29.6817
2010's3 (23.08)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
1,2-dimethylhydrazine[no description available]medium10hydrazinesalkylating agent;
carcinogenic agent
atropine[no description available]medium20
guanethidine[no description available]medium10azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
dimethylhydrazines[no description available]medium10
proroxan[no description available]medium40
phenazepam[no description available]medium10
lithium[no description available]medium20alkali metal atom
pentobarbital[no description available]medium10barbituratesGABAA receptor agonist
amphetamine[no description available]medium10primary amine
cocaine[no description available]medium10benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
naloxone[no description available]medium20morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
morphine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
muramidase[no description available]medium10
clonidine[no description available]medium10clonidine;
imidazoline
dobutamine[no description available]medium10catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
reserpine[no description available]medium10alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
berotek[no description available]medium10resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
propranolol[no description available]medium10naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
phenylephrine[no description available]medium10phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
dicarbine[no description available]medium10
lithium chloride[no description available]medium10inorganic chloride;
lithium salt		antimanic drug;
geroprotector
chlorine[no description available]medium10halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
ANS (Autonomic Nervous System) Diseases0medium11
ANS Diseases0medium11
Autonomic Central Nervous System Diseases0medium11
Autonomic Diseases0medium11
Autonomic Nervous System Diseases0medium11
Autonomic Nervous System Disorders0medium11
Autonomic Peripheral Nervous System Diseases0medium11
Cancer of Colon0low10
Cancer of the Colon0low10
Central Autonomic Nervous System Diseases0medium11
Chemical Dependence0low10
Clostridium tetani Infection0low20
Colon Cancer0low10
Colon Neoplasms0low10
Colonic Cancer0low10
Colonic Neoplasms0low10
Curling Ulcer0medium11
Curling's Ulcer0medium11
Disorders of the Autonomic Nervous System0medium11
Drug Abuse0low10
Drug Addiction0low10
Drug Dependence0low10
Drug Habituation0low10
Drug Use Disorders0low10
Duodenal Ulcer0medium11
Duodenitis0medium11
Erosive Duodenitis0medium11
Experimental Neoplasms0low10
Frostbite0low10
Gastroenteritis0medium11
Inflammation0low10
Innate Inflammatory Response0low10
Neoplasms, Colonic0low10
Neoplasms, Experimental0low10
Nervous System Diseases, Autonomic0medium11
Nervous System Diseases, Parasympathetic0medium11
Nervous System Diseases, Sympathetic0medium11
Organic Mental Disorders, Substance-Induced0low10
Parasympathetic Nervous System Diseases0medium11
Peripheral Autonomic Nervous System Diseases0medium11
Prescription Drug Abuse0low10
Segmental Autonomic Dysfunction0medium11
Substance Abuse0low10
Substance Addiction0low10
Substance Dependence0low10
Substance Use0low10
Substance Use Disorders0low10
Substance-Related Disorders0low10
Sympathetic Nervous System Diseases0medium11
Tetanus0low20